DTech Liquidating

DTech Liquidating Change in Working Capital

Delisted

The Change in Working Capital of DTech Liquidating (DMTKQ) as of Nov 18, 2026 is 11,000.00 USD. In the previous year, Change in Working Capital was -2.56 M USD — a change of -100.43% (higher).

Change in Working Capital

11,000.00USD

YoY

-100.43%

Last updated:

Change in Working Capital of DTech Liquidating is 2023 11,000.00 USD. Change in Working Capital of DTech Liquidating was 2022 -2.56 M USD. It decreases by -100.43% higher compared to the previous year.

The DTech Liquidating Change in Working Capital history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Change in Working Capital
Date
Change in Working Capital
Jan 1, 2016
0.00 USD
Jan 1, 2017
-70,000.00 USD
Jan 1, 2018
1.53 M USD
Jan 1, 2019
660,000.00 USD
Jan 1, 2020
1.12 M USD
Jan 1, 2021
-1.20 M USD
Jan 1, 2022
-2.56 M USD
Jan 1, 2023
11,000.00 USD
The DTech Liquidating Change in Working Capital history
YEARChange in Working CapitalYoY
11,000.00USD-100.43%
-2.56 MUSD+113.33%
-1.20 MUSD-207.14%
1.12 MUSD+69.70%
660,000.00USD-56.86%
1.53 MUSD-2,285.71%
-70,000.00USD—
0.00USD—
0.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

DTech Liquidating Stock analysis

What does DTech Liquidating do? DermTech, Inc. develops and sells non-invasive genomics tests for skin disease diagnosis and treatment, focusing on melanoma detection. The company's primary product, the DermTech Melanoma Test (DMT), marketed as Pigmented Lesion Assay (PLA), analyzes skin samples collected via Smart Stickers to identify genomic markers linked to melanoma. Healthcare providers and dermatologists purchase these tests to assess pigmented skin lesions, addressing unmet needs in diagnosing melanoma early. The company's technology enables non-invasive early detection of higher-risk lesions, reducing unnecessary biopsies. DermTech's commercial test targets the diagnostic pathway for pigmented skin lesions, commonly known as moles, which are dark-colored patches of skin. The firm's focus on inflammatory skin diseases and aging-related skin conditions complements its melanoma detection offerings. By enhancing early melanoma detection through genomic analysis, DermTech provides a solution for clinicians managing skin cancer risks without invasive procedures. The company's products are designed to facilitate clinical assessment of skin lesions that raise melanoma concerns, streamlining the diagnostic process. DermTech's approach to non-invasive testing supports healthcare systems by improving efficiency in skin cancer management. The firm's technology specifically addresses genomic markers associated with melanoma, offering a targeted solution for high-risk lesion identification. DTech Liquidating is one of the most popular companies on Eulerpool.

Frequently Asked Questions about DTech Liquidating stock

Change in Working Capital of DTech Liquidating is 11,000.00 USD in 2023.

Change in Working Capital of DTech Liquidating changed from -2.56 M USD to 11,000.00 USD, representing a -100.43% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Change in Working Capital DTech Liquidating since 2006 – with annual values, charts, and detailed analysis.

Change in working capital reflects the period-over-period change in current assets minus current liabilities. It impacts operating cash flow significantly.

Change in Working Capital's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Change in Working Capital's DTech Liquidating historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — DTech Liquidating

All Key Metrics — DTech Liquidating